![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Pharmacokinetic Interaction Of HCV Protease Inhibitor MK-5172 and Ritonavir in Healthy Subjects
|
|
|
Reported by Jules Levin
Presented at HEPDART 2013: Frontiers in Drug Development for Viral Hepatitis, December 8-12, 2013, Big Island, Hawaii
WW Yeh1, IP Fraser1, C Reitmann1, L Caro1, A Mitselos2, J-F Denef2, I De Lepeleire2, JN de Hoon3, C Vandermeulen3, JA Wagner1, JR Butterton1
1Merck & Co., Inc., Whitehouse Station, NJ, 2Merck, Sharp & Dohme, Brussels, Belgium, 3Universitair Ziekenhuis Leuven, Campus Gathuisberg, Center for Clinical Pharmacology, Leuven, Belgium
![AASLD1.gif](../images/121613/121613-1/AASLD1.gif)
![AASLD2.gif](../images/121613/121613-1/AASLD2.gif)
![AASLD3.gif](../images/121613/121613-1/AASLD3.gif)
![AASLD4.gif](../images/121613/121613-1/AASLD4.gif)
![AASLD5.gif](../images/121613/121613-1/AASLD5.gif)
![AASLD6.gif](../images/121613/121613-1/AASLD6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|